New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
09:12 EDTSNE, RPRX, MW, ROP, JOSB, FURX, KERX, BBY, HES, CAT, BBBYOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Caterpillar (CAT), up 2.5%... ALSO HIGHER: Hess (HES), up 6.6% after announcing intent to pursue sale of terminal network, saying Elliott Associates may acquire more shares... Sony (SNE), up 7% following upgrade to Buy at Citigroup... Best Buy (BBY), up 3.2% following upgrade to Buy at BB&T... Keryx Biopharmaceuticals (KERX), up 45% after Zerenex meets primary study endpoint... Furiex (FURX), up 47% after confirming Takeda's receipt of FDA approval for certain drugs, Canaccord initiates stock with a Buy... DOWN AFTER EARNINGS/GUIDANCE: JoS. A. Bank (JOSB), down 16.6%... Roper (ROP), down 2.8%... ALSO LOWER: Men's Wearhouse (MW), down 3.5% after peer JoS. A. Bank's warns on Q4 results... Repros Therapeutics (RPRX), down 5.7% after revising date for expected clinical results from study of Androxal... Bed Bath & Beyond (BBBY), down 2.4% following downgrade to Sell at Goldman.
News For SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY From The Last 14 Days
Check below for free stories on SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 5, 2014
13:56 EDTKERXKeryx bounces off low following halt, levels to watch
Subscribe for More Information
13:44 EDTKERXKeryx reopens, down 12.5% to $15.74 after FDA approval of Ferric Citrate
13:27 EDTKERXKeryx label for Ferric Citrate positive, says Maxim
Maxim views the label for Keryx' newly-approved Ferric Citrate as a positive that suggests the drug could become the category leader. The firm noted the FDA is deliberating on NCE Status for the drug, which it also views as appearing positive, since the agency has rejected others. Maxim maintains its Buy rating and $24 price target on the stock, which remains halted for trade, with trading set to resume at 1:40 pm ET.
13:20 EDTKERXKeryx to resume trading at 1:40 pm ET
Subscribe for More Information
11:19 EDTKERXKeryx receives FDA approval of Ferric Citrate
Subscribe for More Information
10:50 EDTKERXKeryx trading halted, pending news
September 4, 2014
13:59 EDTCATProgress Rail loses railcar improvement deals, WSJ says
Subscribe for More Information
12:16 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Subscribe for More Information
12:08 EDTKERXAnalysts split on Keryx ahead of FDA action date
Subscribe for More Information
08:30 EDTKERXFBR not a buyer of Keryx ahead of PDUFA date
Subscribe for More Information
07:36 EDTRPRXRepros Therapeutics weakness a buying opportunity, says Brean Capital
Brean Capital said the recent weakness in Repros Therapeutics is a buying opportunity. The firm said concerns over the upcoming FDA meeting are overblown and shares were substantially oversold in response to negative commentary yesterday. Shares of Repros Therapeutics remain Buy rated with a $41 price target.
September 3, 2014
16:20 EDTRPRXOn The Fly: Closing Wrap
Stocks on Wall Street began the session in positive territory after Russian President Vladimir Putin said he had an outline for a cease-fire plan for eastern Ukraine and was closing in an agreement. The averages hit their highs shortly after the open and the Nasdaq was the first index to cross into negative territory as it was weighed down by Apple's (AAPL) decline. The market moved in a narrow range as investors anticipated the Fedís Beige Book report, scheduled for release mid-afternoon. The report was fairly benign and the market limped into the close, with volume remaining light. ECONOMIC EVENTS: U.S. factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book stated that the pace of growth did not change significantly in any of the central bank's 12 regions during a six week period ended in August compared with the previous six week period. COMPANY NEWS: Shares of Apple retreated $4.36, or 4.22%, to $98.94 after research firm Pacific Crest advised investors to take some profits in the stock. Analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which surged $4.81, or 44.05%, to $15.73 after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which jumped $3.94, or 9.16%, to $46.97 ahead of its second quarter earnings report, which is due tomorrow morning. Among the noteworthy losers was Repros Therapeutics (RPRX), which fell $4.11, or 18.55%, to $18.05 after FDA briefing documents ahead of a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower after its earnings report was apparel company Vince Holding (VNCE), which fell $4.47, or 11.54%, to $34.27. Analysts at Piper Jaffray attributed the post-earnings weakness to investor concerns over heightened inventory levels, but the firm said it still sees Vince as one of the best small cap growth names in its space and would be "aggressive buyers" on the weakness. INDEXES: The Dow edged up 10.72, or 0.06%, to 17,078.28, the Nasdaq fell 25.62, or 0.56%, to 4,572.56, and the S&P 500 slipped 1.56, or 0.08%, to 2,000.72.
12:33 EDTRPRXOn The Fly: Midday Wrap
Stocks on Wall Street were higher to begin the day, as reports spurred optimism that a ceasefire agreement between Russia and the Ukraine may soon be reached. The move was short lived, as the averages turned mixed during the second hour of trading. Shares of Apple (AAPL) are weighing down the Nasdaq after an analyst recommended investors take some profits in the stock. ECONOMIC EVENTS: In the U.S., factory orders rose 10.5% in July, which was a bit below the forecast for 11.0% growth. The Fed's Beige Book is scheduled to be released at 2:00 pm ET. In Europe, the final reading of Eurozone services PMI was knocked down to 53.1 from a preliminary 53.5 reading, mirroring the lowering of the Eurozone manufacturing PMI reading yesterday. COMPANY NEWS: Shares of Apple retreated 4% after research firm Pacific Crest advised investors to take some profits in the stock. Pacific Crest analyst Andy Hargreaves forecast the percentage of new iPhone users who buy the next version of the device beyond the iPhone 6 is likely to decline versus prior cycles. The stock likely has only limited room to increase, according to Hargreaves, who said he would probably downgrade Apple unless new products that can generate billions of dollars in new operating profit are launched at its September 9 event... Carmakers reported on August vehicle sales in the U.S., with Chrysler (FIATY) reporting a 20% increase, Ford stating that sales rose slightly compared to the prior year and General Motors (GM) posting a 1.2% decline in sales. MAJOR MOVERS: Among the notable gainers was Infinity Pharmaceuticals (INFI), which jumped 46% after the company announced a cancer drug collaboration with AbbVie (ABBV) and a master clinical supply agreement with Roche (RHHBY). Also higher was Mobileye (MBLY), which gained nearly 10% after Morgan Stanley wrote that the stock could rise "towards $100" if the company maintains its current market, gross margins and earnings position. Mobileye is scheduled to report on its second quarter results tomorrow morning, which will be its first quarterly report since its August IPO. Among the noteworthy losers was Repros Therapeutics (RPRX), which dropped 15% after newly posted FDA briefing documents regarding a panel on T-normalizing therapies prompted Piper Jaffray to downgrade the stock to Neutral from Overweight. Also lower following its earnings report was apparel company Vince Holding (VNCE), which fell 11%. INDEXES: Near midday, the Dow was up 33.71, or 0.2%, to 17,101.27, the Nasdaq was down 23.24, or 0.51%, to 4,574.95, and the S&P 500 was down 0.64, or 0.03%, to 2,001.64.
11:13 EDTRPRXRepros Therapeutics downgraded to Neutral at Piper Jaffray
Subscribe for More Information
11:09 EDTRPRXRepros Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
07:31 EDTKERXKeryx could be up another 10%-15% on FDA approval, says JPMorgan
Subscribe for More Information
07:18 EDTSNETime Warner pursues Sony exec for Turner post, NY Post says
Time Warner's (TWX) Turner Broadcasting is pursuing Sony Pictures TV (SNE) executive Zack Van Amburg to become the unit's new entertainment chief after the departure of Steve Koonin, said the New York Post, citing sources. Reference Link
06:07 EDTMWJos. A. Bank announces early termination agreement with Jim's Formal Wear
Subscribe for More Information
September 2, 2014
09:04 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Keryx September call option implied volatility is at 109, October is at 79, December is at 71; compared to its 26-week average of 76 according to Track Data, suggesting large near term price movement into the September 7th PDUFA date for Zerenex.
06:34 EDTBBYApple cuts iPad mini prices as non-Apple vendors may follow, DigiTimes says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use